PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect.Journal of lipid and atherosclerosis · 2025
   Review
2. Acetylation-regulated DUSP1 deficiency contributes to renal fibrosis progression.Theranostics · 2025
   Article
3. YAP/TAZ as master regulators in liver regeneration and disease: insights into mechanisms and therapeutic targets.Molecular biology reports · 2024
   Review
4. PP2C phosphatases-terminators of suicidal thoughts.Cell death & disease · 2024
   Review

Corrections and comments

• Commented on by
  PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling.2016
• Comment on
  PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling.2006

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as